## Tanja Kaartinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1909670/publications.pdf

Version: 2024-02-01

933447 1372567 11 529 10 10 citations h-index g-index papers 11 11 11 908 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Small-bowel mucosal transglutaminase 2-specific IgA deposits in coeliac disease without villous atrophy: A prospective and randomized clinical study. Scandinavian Journal of Gastroenterology, 2005, 40, 564-572.	1.5	140
2	Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy, 2017, 19, 689-702.	0.7	80
3	Resurrection of gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional diagnostic benefit. Scandinavian Journal of Gastroenterology, 2007, 42, 1428-1433.	1.5	78
4	A robust and reproducible animal serum-free culture method for clinical-grade bone marrow-derived mesenchymal stromal cells. Cytotechnology, 2016, 68, 891-906.	1.6	46
5	The shared CTLA4-ICOS risk locus in celiac disease, IgA deficiency and common variable immunodeficiency. Genes and Immunity, 2009, 10, 151-161.	4.1	45
6	The Utilization of Freezing Steps in Mesenchymal Stromal Cell (MSC) Manufacturing: Potential Impact on Quality and Cell Functionality Attributes. Frontiers in Immunology, 2019, 10, 1627.	4.8	38
7	Performance of a new rapid whole blood coeliac test in adult patients with low prevalence of endomysial antibodies. Digestive and Liver Disease, 2007, 39, 1057-1063.	0.9	34
8	Eosinophil Cationic Protein in Human Milk Is Associated with Development of Cow's Milk Allergy and Atopic Eczema in Breast-fed Infants. Pediatric Research, 2004, 55, 296-301.	2.3	24
9	Genetic variation in ICOS regulates mRNA levels of ICOS and splicing isoforms of CTLA4. Molecular Immunology, 2007, 44, 1644-1651.	2.2	22
10	Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety. Molecular Therapy - Methods and Clinical Development, 2018, 9, 109-118.	4.1	22
11	<i>In vitro</i> Treg expansion favors the full-length splicing isoform of CTLA4. Immunotherapy, 2016, 8, 541-553.	2.0	o